China Pharma Holdings (CPHI) Gross Margin (2010 - 2026)

China Pharma Holdings (CPHI) has reported Gross Margin for 17 consecutive years, with 8.81% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin rose 1729.0% year-over-year to 8.81%; the trailing twelve-month figure through Jun 2026 stood at 11.76% (up 3230.0% YoY), and the FY2025 full-year result was 3.18%, up 4066.0% from the prior year.
• Gross Margin fell to 8.81% in Q2 2026 per CPHI's latest filing, from 29.03% in the prior quarter.
• Across five years, Gross Margin topped out at 29.03% in Q1 2026 and bottomed at 109.78% in Q2 2024.
• Historically, Gross Margin has averaged 12.32% across 5 years, with a median of 9.52% in 2022.
• The sharpest annual moves came in 2024 and 2025: Gross Margin slumped 9642 bps in 2024, then jumped 10130 bps in 2025.
• Over 5 years, Gross Margin stood at 1.46% in 2022, then sank by 352 bps to 3.68% in 2023, then sank by 285 bps to 14.16% in 2024, then jumped by 187 bps to 12.3% in 2025, then fell by 28 bps to 8.81% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 8.81%, 29.03%, and 12.3% for Q2 2026, Q1 2026, and Q4 2025 respectively.